百健(BIIB.US)及卫材(ESALF.US)旗下阿尔茨海默症药物Leqembi在英国获得上市许可

智通财经08-22

智通财经APP获悉，百健(BIIB.US)及其日本合作伙伴卫材(ESALF.US)周四宣布，旗下突破性阿尔茨海默症治疗药物Leqembi (lecanemab)已在英国获得营销许可，英国成为欧洲第一个批准该药物的国家。此次批准主要基于卫材Clarity AD临床试验的3期数据，该药物达到了主要终点和所有关键次要终点，结果具有统计学意义。该药物针对阿尔茨海默症的潜在病因。Lecanemab是一种...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2461318747?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-22 19:30","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2461318747","market":"us","top_or_hot":-1,"title":"百健(BIIB.US)及卫材(ESALF.US)旗下阿尔茨海默症药物Leqembi在英国获得上市许可","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，百健(BIIB.US)及其日本合作伙伴卫材(ESALF.US)周四宣布，旗下突破性阿尔茨海默症治疗药物Leqembi (lecanemab)已在英国获得营销许可，英国成为欧洲第一个批准该药物的国家。此次批准主要基于卫材Clarity AD临床试验的3期数据，该药物达到了主要终点和所有关键次要终点，结果具有统计学意义。该药物针对阿尔茨海默症的潜在病因。Lecanemab是一种...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221936199f47d874&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百健(BIIB.US)及卫材(ESALF.US)旗下阿尔茨海默症药物Leqembi在英国获得上市许可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百健(BIIB.US)及卫材(ESALF.US)旗下阿尔茨海默症药物Leqembi在英国获得上市许可\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-22 19:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221936199f47d874&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，百健(BIIB.US)及其日本合作伙伴卫材(ESALF.US)周四宣布，旗下突破性阿尔茨海默症治疗药物Leqembi (lecanemab)已在英国获得营销许可，英国成为欧洲第一个批准该药物的国家。此次批准主要基于卫材Clarity AD临床试验的3期数据，该药物达到了主要终点和所有关键次要终点，结果具有统计学意义。该药物针对阿尔茨海默症的潜在病因。Lecanemab是一种...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221936199f47d874&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221936199f47d874&s=b","article_id":"2461318747","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221936199f47d874&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2461318747","pubTimestamp":1724326253,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"智通财经APP获悉，百健及其日本合作伙伴卫材周四宣布，旗下突破性阿尔茨海默症治疗药物Leqembi 已在英国获得营销许可，英国成为欧洲第一个批准该药物的国家。2024年1月，中国批准了Leqembi作为治疗阿尔茨海默症引起的轻度认知障碍和轻度痴呆的药物，成为继美国和日本之后第三个批准Leqembi的国家。随着百健主打的多发性硬化症药物销量下滑，该公司正寻求提振Leqembi的销量。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4532":"文艺复兴科技持仓","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","ESALF":"Eisai Co., Ltd.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","BIIB":"渤健公司","BK4139":"生物科技","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4588":"碎股","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4007":"制药","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H"},"translate_title":"Biogen (BIIB.US) and Eisai (ESALF.US) 's Alzheimer's drug Leqembi obtained marketing authorization in the UK","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1,"ESALF":1},"content_text":"智通财经APP获悉，百健(BIIB.US)及其日本合作伙伴卫材(ESALF.US)周四宣布，旗下突破性阿尔茨海默症治疗药物Leqembi (lecanemab)已在英国获得营销许可，英国成为欧洲第一个批准该药物的国家。此次批准主要基于卫材Clarity AD临床试验的3期数据，该药物达到了主要终点和所有关键次要终点，结果具有统计学意义。该药物针对阿尔茨海默症的潜在病因。Lecanemab是一种人源化免疫球蛋白γ1单克隆抗体，据说是唯一被批准的治疗阿尔茨海默氏症的药物，可以降低疾病进展速度，减缓认知和功能衰退。在英国，lecanemab被用于治疗载脂蛋白Eε4 (ApoEε4)杂合子或非携带者的成年患者因阿尔茨海默症引起的轻度认知障碍和轻度痴呆。2024年1月，中国批准了Leqembi作为治疗阿尔茨海默症引起的轻度认知障碍和轻度痴呆的药物，成为继美国和日本之后第三个批准Leqembi的国家。卫材是该药的主要开发商，百健协助其商业化。两家公司将在英国共同推广该药物，卫材作为营销授权持有人分销该产品。本月初，百健公布了第二季度财报，并提高了全年利润预期。二季报显示，与日本卫材合作开发的阿尔茨海默症药物Leqembi的销售额约为4000万美元，远高于第一季度的1,900万美元。随着百健主打的多发性硬化症药物销量下滑，该公司正寻求提振Leqembi的销量。此前，欧洲药品监管机构拒绝了该药物，这对两家公司来说是一个挫折。今年7月，美国监管机构批准了礼来一种与之竞争的阿尔茨海默病治疗药物。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461318747"}